跳转至内容
Merck
  • ARL3 activation requires the co-GEF BART and effector-mediated turnover.

ARL3 activation requires the co-GEF BART and effector-mediated turnover.

eLife (2021-01-14)
Yasmin ElMaghloob, Begoña Sot, Michael J McIlwraith, Esther Garcia, Tamas Yelland, Shehab Ismail
摘要

The ADP-ribosylation factor-like 3 (ARL3) is a ciliopathy G-protein which regulates the ciliary trafficking of several lipid-modified proteins. ARL3 is activated by its guanine exchange factor (GEF) ARL13B via an unresolved mechanism. BART is described as an ARL3 effector which has also been implicated in ciliopathies, although the role of its ARL3 interaction is unknown. Here, we show that, at physiological GTP:GDP levels, human ARL3GDP is weakly activated by ARL13B. However, BART interacts with nucleotide-free ARL3 and, in concert with ARL13B, efficiently activates ARL3. In addition, BART binds ARL3GTP and inhibits GTP dissociation, thereby stabilising the active G-protein; the binding of ARL3 effectors then releases BART. Finally, using live cell imaging, we show that BART accesses the primary cilium and colocalises with ARL13B. We propose a model wherein BART functions as a bona fide co-GEF for ARL3 and maintains the active ARL3GTP, until it is recycled by ARL3 effectors.

材料
货号
品牌
产品描述

Sigma-Aldrich
鸟苷5′-三磷酸 钠盐 水合物, ≥95% (HPLC), powder
Sigma-Aldrich
凝血酶 来源于牛血浆, lyophilized powder, 40-500 NIH units/mg protein (biuret)
Sigma-Aldrich
鸟苷 5'-二磷酸 钠盐, Type I, ≥96% (HPLC)
Sigma-Aldrich
肉豆蔻酰辅酶A 锂盐, ≥80.0%